Risk of adverse cardiovascular events with use of inhaled long-acting bronchodilators in management of chronic obstructive pulmonary disease.
J Food Drug Anal
; 27(3): 657-670, 2019 07.
Article
em En
| MEDLINE
| ID: mdl-31324282
ABSTRACT
Inhaled long-acting bronchodilators, including long-acting ß2 agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are the mainstay therapy in the treatment of chronic obstructive pulmonary disease (COPD), a disease that poses a heavy burden on morbidity and mortality worldwide. Use of LABAs and LAMAs in patients with COPD, however, has been concerned about an increased risk of adverse cardiovascular events, despite inconsistent findings reported from randomized controlled trials (RCTs) and observational studies. In this review, we detailed the relevant evidence generated from RCTs and observational studies with respect to the risk of cardiovascular disease with use of LABAs and LAMAs in management of COPD, and analyzed the contradictory findings in the literature, as well as recommended future research directions to clear the air regarding the cardiovascular safety of inhaled long-acting bronchodilators.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Broncodilatadores
/
Doenças Cardiovasculares
/
Doença Pulmonar Obstrutiva Crônica
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article